Download Sample
Add to CartGlobal Animal Model Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Animal Type;
Pigs, Cats, and Mice.By Technology;
CRISPR, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Others.By Application;
Research & Development, Production, and Quality Control.By Use;
Human and Veterinary.By End-Use;
Companies and Organizations.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Animal Model Market (USD Million), 2021 - 2031
In the year 2024, the Global Animal Model Market was valued at USD 11,328.38 million. The size of this market is expected to increase to USD 18,072.23 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.9%.
The global animal model market plays a pivotal role in advancing biomedical research and drug development, serving as indispensable tools in understanding human diseases and testing potential therapies. These models, predominantly mice, rats, and other species genetically engineered to mimic human conditions, are instrumental in studying complex biological processes at a systemic and molecular level. They enable researchers to investigate disease mechanisms, evaluate drug efficacy and safety, and explore genetic modifications that may inform medical breakthroughs.
In recent years, the demand for animal models has surged alongside the rapid expansion of pharmaceutical and biotechnology industries, where they are essential for preclinical testing. Their use extends beyond drug development to encompass a broad spectrum of research areas, including immunology, neuroscience, oncology, and toxicology. The ability to replicate human diseases within controlled laboratory environments not only accelerates the pace of scientific discovery but also enhances the accuracy of predicting human responses to treatments.
Ethical considerations and advancements in technology have spurred innovation in the animal model market, driving the development of more sophisticated models that better mimic human physiology. These advancements include the creation of humanized models incorporating human genes, cells, or tissues, which offer more precise representations of human disease states and responses to therapies. Such innovations not only improve research outcomes but also address ethical concerns by reducing the overall number of animals used in experimentation.
The global landscape of the animal model market is shaped by regulatory frameworks that govern the ethical use and welfare of animals in research. Strict adherence to these regulations ensures humane treatment and responsible scientific practices while fostering public trust in biomedical research. As the demand for personalized medicine grows, so too does the need for animal models that can accurately reflect the genetic diversity and complexities of human populations.
In conclusion, the animal model market stands as a cornerstone of modern biomedical research, driving innovation and progress in understanding and treating human diseases. Through ongoing advancements in technology and ethical practices, these models continue to evolve, offering invaluable insights that pave the way for novel therapies and medical solutions. As global research efforts intensify, the role of animal models remains indispensable in shaping the future of healthcare and improving human quality of life.
Global Animal Model Market Recent Developments
-
In order to differentiate antibody-drug R&D from preclinical models and services (BioMice), Biocytogen formed two business divisions in August 2023.
-
Merck strengthened its immunology program in April 2023 when it acquired Prometheus Biosciences, Inc.
-
CareDx and Miromatrix established an exclusive collaboration in April 2023 to further research on bioengineered organs for transplantation into humans.
-
AstraZeneca successfully completed the purchase of CinCor Pharma, Inc. (CinCor) in February 2023. CinCor is a clinical-stage biopharmaceutical business based in the US that focuses on developing innovative medicines for chronic kidney disease and resistant and uncontrolled hypertension.
Segment Analysis
The global animal model market is categorized into several species types, including mice, rats, rabbits, and others such as guinea pigs, pigs, and dogs. Among these, mice hold the largest market share due to their genetic similarities to humans, ease of genetic manipulation, and high reproductive rates, making them ideal for genetic, cancer, and immunology studies. Rats follow closely, valued for their larger size which facilitates surgical procedures and studies in toxicology and neurology. The demand for rabbits is also significant, particularly in the field of antibody production and ophthalmology. Other species like guinea pigs and dogs are used in specialized research areas, providing essential models for studying complex diseases and therapeutic responses.
Animal models are extensively utilized across various applications including drug discovery and development, basic research, toxicology, and others like diagnostics and regulatory testing. Drug discovery and development dominate the application segment as animal models play a crucial role in preclinical trials to assess the efficacy and safety of new drugs. Basic research is another critical segment, where animal models are indispensable for understanding disease mechanisms and biological processes. Toxicology testing is essential for evaluating the safety of chemicals, pharmaceuticals, and other products, thus ensuring regulatory compliance. Other applications, such as diagnostics, also rely on animal models for developing and validating new diagnostic tools and procedures.
The end users of the global animal model market include pharmaceutical and biotechnology companies, academic and research institutions, and contract research organizations (CROs). Pharmaceutical and biotechnology companies represent the largest end-user segment due to their extensive use of animal models in drug development pipelines. These companies invest heavily in preclinical research to meet stringent regulatory requirements and to bring new therapies to market. Academic and research institutions are vital contributors, utilizing animal models for fundamental research and scientific advancements. CROs are gaining traction as they provide specialized services, including animal model-based testing and research, helping to streamline operations and reduce costs for their clients.
Geographically, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America leads the market due to a strong presence of pharmaceutical companies, advanced research infrastructure, and significant funding for biomedical research. Europe follows closely, driven by robust research activities and supportive regulatory frameworks. The Asia-Pacific region is experiencing rapid growth, fueled by increasing investments in research and development, growing pharmaceutical industries, and rising healthcare expenditure. Latin America and the Middle East & Africa, although smaller in market share, are showing promising growth potential due to improving research capabilities and increased focus on healthcare innovations.
The global animal model market is poised for substantial growth, driven by advancements in biomedical research, increasing drug discovery activities, and rising demand for personalized medicine. Each segment, whether by species type, application, end user, or region, contributes uniquely to the market dynamics, reflecting the diverse and critical roles animal models play in scientific and medical advancements.
Global Animal Model Segment Analysis
In this report, the Global Animal Model Market has been segmented by Animal Type, Technology, Application, Use, End-Use and Geography.
Global Animal Model Market, Segmentation by Animal Type
The Global Animal Model Market has been segmented by Animal Type into Pigs, Cats, and Mice.
The global animal model market encompasses a diverse range of animal types crucial to scientific research and pharmaceutical development. Among these, pigs, cats, and mice stand out as key models used extensively across various disciplines. Pigs, with their physiological similarities to humans, are valuable for studying diseases and testing medical treatments. Their larger size allows for procedures and observations that closely mimic human conditions, making them particularly relevant in fields like cardiology and transplantation research.
Cats also play a significant role in scientific studies, particularly in neuroscience and ophthalmology. Their neural systems closely resemble humans', making them suitable for investigating sensory perception and vision-related disorders. Mice, on the other hand, are perhaps the most widely used animal model due to their genetic similarity to humans, ease of breeding, and cost-effectiveness. They are indispensable in studying genetics, immunology, and cancer research, among other areas.
The animal model market continues to evolve with advancements in genetic engineering and ethical considerations. There is a growing trend towards developing genetically modified animal models that mimic specific human diseases more accurately. Additionally, efforts are ongoing to refine experimental techniques to minimize animal suffering while maximizing scientific insights. As research demands expand, the role of animal models remains pivotal in advancing medical knowledge and therapeutic development globally.
Global Animal Model Market, Segmentation by Technology
The Global Animal Model Market has been segmented by Technology into CRISPR, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Others.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionized genetic engineering by enabling precise modifications in animal genomes. It allows researchers to edit genes with unprecedented accuracy, making it a powerful tool for creating genetically modified animal models that mimic human diseases or conditions. This technology has significantly accelerated the pace of biomedical research, offering insights into disease mechanisms and potential therapeutic targets.
Microinjection is another crucial technique in the animal model market, particularly for generating transgenic animals. It involves the direct injection of genetic material into a fertilized egg, allowing researchers to introduce foreign genes or modify existing ones. This method is essential for studying gene function, disease modeling, and testing potential therapies.
Embryonic stem cell injection involves the introduction of genetically modified embryonic stem cells into early-stage embryos, facilitating the development of chimeric animals with altered genetic characteristics. This approach is instrumental in studying developmental biology, regenerative medicine, and understanding complex genetic interactions.
Nuclear transfer, often associated with cloning, involves transferring a nucleus from a donor cell into an enucleated egg cell, which can then develop into an animal with identical genetic material to the donor. While controversial, this technology has contributed to advancements in agriculture, conservation biology, and the study of developmental genetics.
Beyond these main technologies, the animal model market encompasses a spectrum of other methodologies tailored to specific research needs. These include viral vector-mediated gene transfer, RNA interference (RNAi), and genome-wide association studies (GWAS), among others. Each technology offers unique advantages and applications, contributing to the comprehensive toolbox available to researchers worldwide.
In conclusion, the global animal model market is dynamic and driven by continuous technological innovation. The integration of CRISPR, microinjection, embryonic stem cell injection, nuclear transfer, and other emerging technologies underscores its pivotal role in advancing scientific discovery, drug development, and personalized medicine. As these technologies evolve, they promise to further enhance our understanding of biological processes and diseases, ultimately improving human and animal health outcomes globally.
Global Animal Model Market, Segmentation by Application
The Global Animal Model Market has been segmented by Application into Research & Development, Production, and Quality Control.
In the realm of research and development, animal models enable scientists to simulate human diseases and conditions, facilitating the study of disease progression and the development of potential treatments. They are instrumental in validating new drug candidates before clinical trials, ensuring safety and efficacy profiles. Moreover, these models contribute significantly to the understanding of biological pathways and mechanisms underlying various diseases, thereby aiding in the discovery of novel therapeutic targets.
In the production phase, animal models are utilized to scale up production processes for biopharmaceuticals and other biological products. They help optimize manufacturing protocols, assess product consistency, and ensure adherence to regulatory standards. Quality control relies heavily on animal models to verify the purity, potency, and safety of pharmaceutical products before they reach the market. These models provide critical data on toxicity, immunogenicity, and other factors essential for regulatory approval and product release.
The market for animal models continues to expand globally, driven by advancements in genetic engineering, increasing investment in biomedical research, and the rising demand for personalized medicine. While ethical considerations and regulatory scrutiny remain paramount, innovations in technology and methodologies promise to enhance the utility and ethical standards of animal models in the future. As the pharmaceutical and biotechnology industries evolve, animal models will remain indispensable in advancing scientific understanding and therapeutic innovation.
Global Animal Model Market, Segmentation by Use
The Global Animal Model Market has been segmented by Use into Human and Veterinary.
The Global Animal Model Market is a dynamic sector driven by advancements in biomedical research and veterinary medicine. Animal models play a crucial role in both human and veterinary applications, serving as essential tools for understanding disease mechanisms, developing treatments, and testing the efficacy of new therapies.
In biomedical research focused on human health, animal models such as mice, rats, and non-human primates are extensively utilized to mimic human diseases and study their progression. These models enable researchers to investigate biological processes, evaluate potential drug candidates, and explore personalized medicine approaches. The insights gained from these studies are pivotal in advancing medical knowledge and developing new treatments for human diseases ranging from cancer to neurological disorders.
In parallel, the veterinary segment of the animal model market addresses the unique health challenges of animals. Animal models are employed to study diseases that affect livestock, pets, and other animals, aiming to improve veterinary care and develop vaccines and treatments. By utilizing animal models, researchers can enhance animal welfare, optimize breeding practices, and ensure the safety and efficacy of veterinary pharmaceuticals.
The segmentation of the animal model market into human and veterinary uses reflects the diverse applications and specialized research needs within these domains. As research methodologies evolve and new technologies emerge, the demand for reliable and ethical animal models continues to grow, driven by the quest for better health outcomes for both humans and animals alike.
Global Animal Model Market, Segmentation by End-Use
The Global Animal Model Market has been segmented by End-Use into Companies and Organizations.
The global animal model market plays a pivotal role in biomedical research, catering primarily to pharmaceutical companies, academic institutions, and contract research organizations (CROs). These entities utilize animal models to mimic human physiological conditions, facilitating the study of diseases, drug development, and testing. Pharmaceutical companies are major stakeholders in this market, relying on animal models to assess the efficacy and safety of new drug candidates before advancing to human clinical trials. Academic institutions also heavily contribute to the market by conducting fundamental research in various fields, including genetics, neuroscience, and oncology, using animal models as essential tools.
In recent years, there has been a notable increase in outsourcing research activities to CROs specializing in preclinical studies. These organizations offer expertise in conducting experiments using animal models, thereby reducing costs and optimizing research timelines for drug development. Moreover, regulatory bodies across the globe mandate rigorous preclinical testing, further driving demand for animal models in compliance with safety and efficacy standards before human trials.
The market for animal models is characterized by a diverse range of species, including rodents, rabbits, dogs, and non-human primates, each chosen based on specific research requirements. Technological advancements in genetic engineering have also revolutionized the market, enabling the creation of genetically modified animal models that closely mimic human diseases and conditions, thereby enhancing the relevance and accuracy of research outcomes.
Ethical considerations regarding animal welfare, coupled with advancements in alternative methods such as in vitro testing and computational modeling, present both challenges and opportunities for the animal model market. While these alternatives aim to reduce reliance on animal testing, the indispensable role of animal models in biomedical research ensures their continued significance in advancing scientific knowledge and medical treatments globally. As such, the market for animal models is expected to evolve with ongoing advancements in research methodologies and regulatory landscapes, influencing stakeholders across pharmaceuticals, academia, and CROs alike.
Global Animal Model Market, Segmentation by Geography
In this report, the Global Animal Model Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Animal Model Market Share (%), by Geographical Region, 2024
The global animal model market is poised for significant growth from 2020 to 2030 across various regions including North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. Animal models play a crucial role in biomedical research, aiding in the study of disease mechanisms, drug development, and testing therapeutic interventions.
North America currently dominates the market, driven by a well-established pharmaceutical and biotechnology sector, extensive research funding, and advanced healthcare infrastructure. The region is expected to maintain its lead throughout the forecast period, supported by ongoing advancements in genetic engineering and a robust regulatory framework that governs the ethical use of animal models in research.
Europe follows closely behind, characterized by significant investments in biomedical research and a strong emphasis on translational medicine. Countries like the UK, Germany, and France are at the forefront due to their prominent academic and research institutions, fostering innovation in disease modeling and preclinical studies.
Asia Pacific is anticipated to witness rapid market growth, propelled by increasing research activities, rising healthcare expenditure, and expanding pharmaceutical and biotechnology industries in countries such as China, Japan, and India. These regions are increasingly becoming attractive destinations for outsourcing preclinical research services, driven by cost-efficiency and a growing pool of skilled researchers.
In the Middle East and Africa, the market is expected to grow steadily, supported by improving healthcare infrastructure, rising investments in research and development, and government initiatives aimed at enhancing the region's biomedical research capabilities.
Latin America also presents opportunities for market expansion, driven by expanding pharmaceutical and biotechnology sectors, increasing awareness about the benefits of animal models in research, and collaborations with international research organizations.
Overall, the global animal model market is set to experience robust growth over the next decade, driven by technological advancements, increasing prevalence of chronic diseases, and the growing demand for personalized medicine solutions. However, ethical considerations regarding animal welfare and stringent regulations governing their use in research remain key challenges that stakeholders must navigate to ensure sustainable growth in the market.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Animal Model Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Increasing pet ownership
- Rising prevalence of zoonotic diseases
- Growing demand for protein-rich diets
-
Government initiatives promoting animal health -Government initiatives promoting animal health play a pivotal role in shaping the global animal model market. These initiatives encompass a range of activities aimed at enhancing the well-being of animals through research, disease prevention, and treatment advancements. In many countries, governments allocate substantial funding towards veterinary research and development, which directly influences the demand for animal models used in scientific studies. Such initiatives often prioritize the development of new therapies, vaccines, and diagnostic tools to combat prevalent animal diseases and ensure the sustainability of livestock production.
Government regulations and policies regarding animal testing standards also impact the animal model market. Stringent guidelines ensure ethical practices in research involving animals, fostering the development of more humane and effective experimental methods. These regulations not only safeguard animal welfare but also stimulate innovation in the development of alternative testing methods, such as in vitro and computational models, which could potentially reduce the dependence on animal models in research.
Governmental support extends to collaborations between research institutions, pharmaceutical companies, and academic organizations, aiming to accelerate the discovery of novel treatments and vaccines. Such partnerships often leverage animal models to study complex diseases and validate drug efficacy before clinical trials, thereby reducing risks and costs associated with drug development.
In conclusion, government initiatives promoting animal health drive significant growth and innovation within the global animal model market. By fostering research, enhancing regulatory frameworks, and encouraging collaboration, governments play a crucial role in advancing scientific discoveries that benefit both animal and human health worldwide. These efforts ensure that the use of animal models remains integral to biomedical research while upholding ethical standards and promoting advancements in veterinary care and animal welfare.
Restraints:
- High cost of animal healthcare products
- Lack of skilled veterinarians in certain regions
- Resistance to antimicrobial drugs
-
Reimbursement policies for animal treatments -Reimbursement policies play a crucial role in shaping the global animal model market, which is integral to biomedical research and pharmaceutical development. These policies dictate how expenses related to animal treatments and research are covered, influencing the affordability and accessibility of such experiments. In many regions, reimbursement policies vary significantly, impacting the adoption and utilization of animal models in research.
Countries with robust reimbursement frameworks often see higher levels of investment in animal model research, as researchers and pharmaceutical companies are more assured of recovering costs associated with experimental treatments. This financial predictability encourages innovation and experimentation, driving advancements in areas like disease modeling, drug efficacy testing, and toxicity studies.
Regions with less comprehensive reimbursement policies may experience slower growth in their animal model markets. Uncertain financial outcomes can deter stakeholders from investing in extensive research involving animals, thereby potentially limiting scientific progress and therapeutic breakthroughs.
Evolving ethical considerations around animal welfare also influence reimbursement policies, with stricter regulations sometimes leading to higher operational costs and increased scrutiny on the necessity and ethical handling of animal experiments.
In conclusion, while reimbursement policies may seem administrative, they profoundly impact the dynamics of the global animal model market. By providing financial incentives and regulatory frameworks, these policies shape the landscape of biomedical research, impacting innovation, ethical practices, and ultimately the development of new treatments and therapies. Thus, understanding and adapting to these policies is essential for stakeholders in both the research and pharmaceutical sectors to navigate and contribute effectively to this critical field.
Opportunities:
- Expansion in emerging markets
- Development of personalized veterinary medicine
- Focus on preventive healthcare for animals
-
Increasing investments in R&D for innovative products -The global animal model market is experiencing significant growth, driven largely by increasing investments in research and development aimed at developing innovative products. Animal models play a crucial role in biomedical research, providing essential insights into human diseases, drug efficacy, and safety. As pharmaceutical and biotechnology companies continue to expand their pipelines with novel therapeutics, the demand for reliable and predictive animal models has surged.
Investments in R&D are not only fueling advancements in disease modeling and drug discovery but also enhancing the overall quality and diversity of animal models available. This includes genetically engineered models that closely mimic human conditions, thereby improving the translatability of preclinical research to clinical outcomes. The pharmaceutical industry, in particular, relies heavily on animal models to assess drug toxicity, pharmacokinetics, and efficacy before advancing to human trials, thereby reducing risks and costs associated with drug development.
Academic and government research institutions are also contributing to the expansion of the animal model market by conducting fundamental research across a wide range of disciplines, from neuroscience to oncology. This collaborative effort between public and private sectors is fostering innovation and driving the adoption of sophisticated animal models that better reflect human biology.
Advancements in technologies such as CRISPR/Cas9 gene editing and 3D bioprinting are expected to further revolutionize the field by enabling precise modifications and the creation of more complex model systems. These innovations promise to accelerate research timelines and enhance the predictive power of preclinical studies, ultimately leading to the development of safer and more effective therapies.
In conclusion, the global animal model market is poised for continued growth, supported by robust investments in R&D and technological advancements. As stakeholders across various sectors strive to address unmet medical needs and improve healthcare outcomes, the role of animal models as indispensable tools in biomedical research is set to expand, driving innovation and shaping the future of medicine.
Competitive Landscape Analysis
Key players in Global Animal Model Market include.
- Charles River
- Envigo
- genOway
- Harbour BioMed
- Janvier Labs
- PharmaLegacy
- Taconic Biosciences Inc.
- The Jackson Laboratory
- TRANS GENIC INC, Ltd
- BioMice
- Merck strengthened
- CareDx and Miromatrix
- AstraZeneca
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Animal Type
- Market Snapshot, By Technology
- Market Snapshot, By Application
- Market Snapshot, By Use
- Market Snapshot, By End-Use
- Market Snapshot, By Region
- Global Animal Model Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Increasing pet ownership
-
Rising prevalence of zoonotic diseases
-
Growing demand for protein-rich diets
-
Government initiatives promoting animal health
-
- Restraints
-
High cost of animal healthcare products
-
Lack of skilled veterinarians in certain regions
-
Resistance to antimicrobial drugs
-
Reimbursement policies for animal treatments
-
- Opportunities
-
Expansion in emerging markets
-
Development of personalized veterinary medicine
-
Focus on preventive healthcare for animals
-
Increasing investments in R&D for innovative products
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Animal Model Market, By Animal Type, 2021 - 2031 (USD Million)
- Pigs
- Cats
- Mice
- Global Animal Model Market, By Technology, 2021 - 2031 (USD Million)
- CRISPR
- Microinjection
- Embryonic Stem Cell Injection
- Nuclear Transfer
- Others
- Global Animal Model Market, By Application, 2021 - 2031 (USD Million)
- Research & Development
- Production
- Quality Control
- Global Animal Model Market, By Use, 2021 - 2031 (USD Million)
- Human
- Veterinary
- Global Animal Model Market, By End-Use, 2021 - 2031 (USD Million)
- Companies
- Organizations
- Global Animal Model Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Animal Model Market, By Animal Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Charles River
- Envigo
- genOway
- Harbour BioMed
- Janvier Labs
- PharmaLegacy
- Taconic Biosciences Inc.
- The Jackson Laboratory
- TRANS GENIC INC, Ltd
- BioMice
- Merck strengthened
- CareDx and Miromatrix
- AstraZeneca
- Company Profiles
- Analyst Views
- Future Outlook of the Market